【Can-Fite BioPharma-Product CF102】 Can-Fite BioPharma Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson

Partner News

8 April, 2020– Can-Fite BioPharma Ltd. issued an announcement, which is summarized as follows:

 Main study endpoints were dose dependent and significantly achieved

 Prof. Safadi, principal investigator: “The study shows Namodenoson has therapeutic effects with a good safety profile and is a very strong candidate for continued clinical development in the treatment of NAFLD/NASH “

Can-Fite today announced that its Phase II exploratory NAFLD/NASH study with Namodenoson achieved its efficacy endpoints, while continuing to demonstrate a good safety profile.

The Phase II double-blind, placebo-controlled, dose-finding efficacy and safety study enrolled 60 patients with non-alcoholic fatty liver disease (NAFLD) with or without non-alcoholic steatohepatitis (NASH) in three clinical sites in Israel including Hadassah Medical Center, Jerusalem; Rabin Medical Center, Petach Tikva; and Holy Family Hospital, Nazareth; with Prof. Rifaat Safadi as the Principal Investigator. Patients with evidence of an active inflammation were treated twice daily with 12.5 mg (n=21) or 25 mg (n=19) of oral Namodenoson vs. placebo (n=20). The patients were treated for 12 weeks and followed-up until week 16. The study’s end points included among others alanine aminotransferase (ALT) and aspartate aminotransferase (AST) blood level, % of liver fat, liver stiffness, serum adiponectin, leptin and patient’s weight loss.

Therapeutically significant positive data and trends were found as follows:

 ALT and AST – a dose response decrease compared to placebo, indicating a reduction of hepatic inflammation was achieved:

   % of patients who reached ALT normalization at follow up was 36.8% in the 25 mg dose vs. 10% in the placebo (p=0.038). In the 12.5 mg dose, 23.8% was recorded at follow up.

   ALT Change from baseline (CFB) and % change from baseline (PCFB) – in the 25 mg group, CFB decreased by 15.4 U/L (p=0.066) and PCFB by 22% (p=0.079) compared to placebo (1.7 U/L, 3.0%, respectively). In the 12.5 mg group, a decrease CFB of 10.4 U/L and PCFB of 8.2% was recorded.

   AST CFB and PCFB – in the 25 mg group, CFB decreased by 8.1 U/L (p=0.03) and PCFB by 17.9% (p=0.05) compared to placebo (increase of 0.3 U/L, decrease of 1.3%, respectively). In the 12.5 mg group, a decrease in CFB of 7.4 U/L and PCFB of 8.1 % was recorded.

 PCFB of liver fat as measured by PDFF (proton density fat fraction on magnetic resonance imaging) and liver stiffness measured by CAP Fibroscan, showed a trend of decrease in the 25 mg and 12.5 mg groups throughout the study period, reflecting improvement in both parameters.

 Serum adiponection levels increased in the 25 mg by 220 ng/mL and the 12.5 mg dose group by 539 ng/mL (p=0.03). Adiponectin is a cytokine with robust anti-inflammatory and anti-fibrotic effects that is used as a biomarker in NAFLD/NASH trials.

 Body weight – a linear decrease was recorded in the 25 mg and 12.5 mg groups.

 The blood expression level of the A3 adenosine receptor (A3AR) biomarker was stable, demonstrating the presence of the receptor after chronic treatment and reflecting the validity of the target.

 Namodenoson continued to be safe and very well tolerated with no reported drug emergent severe adverse effects and no reported hepatotoxicity.

 All study parameters above continued to improve through week 16.

Prof. Rifaat Safadi commented, “We are very pleased with the outcome of this study which shows clear efficacy and safety. One of the goals of this study was to determine the optimal dosage, and we have achieved that, as it appears from the data that 25 mg is both safe and most effective. Namodenoson is a very strong candidate for continued clinical development in the treatment of NAFLD/NASH, particularly since no other treatment options are approved for this specific and growing unmet need.”

Can-Fite CEO Dr. Pnina Fishman stated, “The data indicate Namodenoson’s robust anti-NAFLD/NASH effects. We are very pleased that the patients benefitted from treatment and we look forward to advancing this into the next phase of clinical development. ”

The NASH market is estimated to reach $35-40 billion by 2025.

The original website link: